


RealRate

PHARMACEUTICAL 2022



Tango Therapeutics Inc. Rank 103 of 475





PHARMACEUTICAL 2022





Tango Therapeutics Inc. Rank 103 of 475

The relative strengths and weaknesses of Tango Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tango Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 102% points. The greatest weakness of Tango Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 43%, being 320% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	492,338
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	40,690
Liabilities, Non-Current	114,718
Other Assets	2,985
Other Compr. Net Income	-782
Other Expenses	292
Other Liabilities	0
Other Net Income	247
Property and Equipment	4,832
Research and Development	77,636
Revenues	37,042
Selling, General and Administrative Expense	17,596

Output Variable	Value in 1000 USD
Assets	500,155
Liabilities	155,408
Expenses	95,524
Stockholders Equity	344,747
Net Income	-58,235
Comprehensive Net Income	-58,626
Economic Capital Ratio	43%